Overview

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation

Status:
Completed

Trial end date:
2016-02-01

Target enrollment:

Participant gender:

Summary

The main purpose of the study is to determine if PF-06700841 is safe and well tolerated when administered to humans. A secondary purpose is to assess what the body does to PF-06700841 and to assess what PF-06700841 does to the body when given as single and multiple doses. The pharmacokinetic properties of different forms of PF-06700841 may be studied (tablet and solution/suspension forms).

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Treatments:

PF-06700841
Pharmaceutical Solutions